NCT05427669View on ClinicalTrials.gov

Adjuvant mFOLFOXIRI vs. mFOLFOX6 in MRD Positive Stage II-III Colorectal Cancer (AFFORD)

PHASE3Not yet recruitingINTERVENTIONAL
Enrollment

340

Participants

Timeline

Start Date

October 9, 2022

Primary Completion Date

July 1, 2025

Study Completion Date

July 1, 2027

Conditions
Colorectal Cancer
Interventions
DRUG

mFOLFOXIRI

mFOLFOXIRI (oxaliplatin 85 mg/m2, irinotecan 150 mg/m2, and folinic acid 400 mg/m2 followed by 5-fluorouracil 2400mg/m2 as a 46-hour continuous infusion on day 1) for 12 cycles at the most

DRUG

mFOLFOX6

mFOLFOX6 (oxaliplatin 85 mg/m2, and folinic acid 400 mg/m2 followed by bolus 5-fluorouracil 400 mg/m2 and 5-fluorouracil 2400mg/m2 as a 46-hour continuous infusion on day 1) for 12 cycles at the most

All Listed Sponsors
lead

Yanhong Deng

OTHER

NCT05427669 - Adjuvant mFOLFOXIRI vs. mFOLFOX6 in MRD Positive Stage II-III Colorectal Cancer (AFFORD) | Biotech Hunter | Biotech Hunter